AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
100 days. 14 executive orders. Some bold healthcare policies.
In this CRA Insights, we assess the actions and impact of the second Trump Administration during the first 100 days that directly affect healthcare policy,...